publication date: Feb. 21, 2014


By Matthew Bin Han Ong

NCI has launched a pilot study to assess whether assigning cancer patients treatment based on the genetic characteristics of their disease can improve outcomes for patients with advanced metastatic solid tumors.

The Molecular Profiling based Assignment of Cancer Therapeutics, or M-PACT, trial is one of the first to use a randomized trial design to assign treatment based on specific mutations.

Initially launched at NCI, the trial will eventually be opened to researchers in the institute’s Early Therapeutics Clinical Trials Network. The plan is to report results by 2017.

M-PACT is being launched at a time when NCI is completing reconstruction of its network of clinical trials cooperative groups. On March 1, the structure of the cooperative groups will be officially replaced by the National Clinical Trials Network.

The new trials signal redistribution of resources on the part of the institute, observers say. (See story on p. 1) Insiders expect that the number of patients enrolled in all NCI-sponsored trials would drop to 17,500 during the current fiscal year.

The study is the first of the four initiatives the institute is about to launch this year. The other trials are:

• ALCHEMIST: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial

• SWOG1400: Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

• NCI-MATCH: Molecular Analysis for Therapy Choice

The objective of these trials is to identify subgroups of patients who … Continue reading 40-08 NCI Launches M-PACT Next-Generation Trial

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.